



Meet Paul

AGE

70

LOCATION

NEW YORK

DIAGNOSED WITH MODERATE-TO-SEVERE
PLAQUE PSORIASIS

2011

STARTED ILUMYA® (TILDRAKIZUMAB) 100 MG/ML

MARCH 2019

Psoriasis Journey

Paul's moderate-to-severe plaque psoriasis symptoms first started to appear on his arms and legs in 2011. His plaques were extremely itchy and they caused a burning sensation after scratching.

Prior to being diagnosed with moderate-to-severe plaque psoriasis, Paul was first diagnosed with eczema. The initial medications that he was prescribed did not help control his moderate-to-severe plaque psoriasis symptoms.

Paul found it hard to get a good night's sleep when his plaques were painful and his symptoms were at their worst.

At work as a hospice volunteer, Paul preferred to cover up with long sleeves to ensure that no one saw his plaques. The painful plaques made it hard for him to focus his energy on his patients.

“Moderate-to-severe plaque psoriasis... it steals your life a little, little by little every day... And now being free of the plaque psoriasis, I mean, it's a newfound freedom.”

Finding ILUMYA®

For Paul, finding the right dermatologist changed his story. After many years, Paul was correctly diagnosed with moderate-to-severe plaque psoriasis in 2019.

“Now that I am almost completely clear, I keep forgetting I even have moderate-to-severe plaque psoriasis.”

His new dermatologist recommended ILUMYA® and described how it worked, potential side effects and the dosing schedule. Paul liked that it was administered in the office by his dermatologist, so he could check in regularly about his symptoms and progress.

After experiencing symptoms of moderate-to-severe plaque psoriasis for more than a decade, Paul was encouraged that ILUMYA® helped patients achieve long-lasting results. In fact, nine out of ten people who achieved clear or almost clear skin after one year were still seeing results five years later.

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common ($\geq 1\%$) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice.

Road to Lasting Skin Clearance

Now that he doesn't have to worry about covering up his flakes, Paul feels comfortable going swimming and wearing shorts and short sleeves again.

With only four doses a year after two starter doses, Paul can focus all his attention on his patients when volunteering instead of thinking about when his next dose would be.

Paul is excited to be social with friends now that he is almost completely free of visible, painful plaques.

People living with moderate-to-severe psoriasis should talk to their doctor to determine what treatment option may be right for them. For more information about ILUMYA®, and a downloadable doctor discussion guide, visit [ILUMYA.com/talk-with-your-dermatologist](https://www.ilumya.com/talk-with-your-dermatologist).

Learn more about the moderate-to-severe plaque psoriasis journeys of patients like Paul [here](#).

ILUMYA® IS IN IT FOR THE LONG HAUL WITH ME



With ILUMYA®, most people with moderate-to-severe plaque psoriasis can achieve clear or almost clear skin in as little as 12 weeks, and 5 years into treatment, it's still going strong.

Here are some reasons to ask your doctor about ILUMYA®:

LONG-LASTING RESULTS
9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results 5 years later

DOSING AROUND YOUR SCHEDULE
4 doses a year after 2 starter doses

WORKS FROM THE INSIDE
ILUMYA® works with the body to balance an overactive immune system, addressing symptoms at the source

AFFORDABLE TREATMENT
Eligible patients may pay just \$5 per dose of ILUMYA®*

* \$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ILUMYA and discuss any questions with your doctor.